Prostate-specific antigen and prostate gland volume: Correlation and clinical application
β Scribed by R. Joseph Babaian; Robert B. Evans; Herbert A. Fritsche
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 304 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
β¦ Synopsis
We studied 103 patients seen in our Prostate Cancer Detection Clinic to determine whether a correlation exists between serum prostate-specific antigen (PSA) values and ultrasound-calculated prostate gland volume. Seventy men (68%) had a PSA value s 4 ngiml (our upper limit of normal). The men were subclassified by prostate gland volume at arbitrary break points. Twenty-five men (24%) had a prostate gland volume ~2 5 cm3; in 96%, the PSA value was s 4 mgiml. Further analysis revealed that the percentage of men with a normal serum PSA value decreased a s the prostate gland volume increased; 65.6% of the group with a gland volume between 25 and 50 cm3 (40 of 61) and 35.5% of the group whose prostate volume exceeded 50 cm3 (6 of 17) had PSA values 514 ngiml. Four men had PSA values >20 ngiml; all had prostate cancer. Cancer was diagnosed in four additional patients, three with PSA values between 5 and 10 ngiml and one with a PSA value <4 ngiml. There appears to be a direct relationship between prostate gland volume and PSA value, as well as a cancer value threshold. The clinical implications of these findings are discussed.
π SIMILAR VOLUMES
## Abstract __Objective:__ To establish the value of serum prostateβspecific antigen (PSA) and prostatespecific antigen per unit volume of prostate gland (PSAD) in detecting prostate carcinoma (CaP) in a hypothetical screening algorithm, a metaβanalysis of the sensitivities, specificities, predicti
## Background: The objective of this study was to correlate the failure pattern of localized prostate carcinoma after radiotherapy (rt) with pretreatment (pretx) psa and post-rt nadir psa, using systematic biopsies and serum psa in the assessment of outcome. ## Methods: From january 1990 to febru
Prostate-specific antigen (PSA) has revolutionized the diagnosis and management of men with prostate cancer. Significant advances have been made since the early development of immunoassays. While PSA is useful for staging and monitoring of established disease, it has shown the greatest utility in th
ated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA)